Capital Insight Partners LLC Has $4.16 Million Stock Holdings in Edwards Lifesciences Corporation (NYSE:EW)

Capital Insight Partners LLC trimmed its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 8.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 57,415 shares of the medical research company's stock after selling 5,077 shares during the quarter. Capital Insight Partners LLC's holdings in Edwards Lifesciences were worth $4,161,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Norges Bank acquired a new position in Edwards Lifesciences during the 4th quarter valued at $610,895,000. Vanguard Group Inc. increased its holdings in Edwards Lifesciences by 10.4% in the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock valued at $5,117,845,000 after buying an additional 6,537,494 shares during the period. Marshall Wace LLP increased its holdings in Edwards Lifesciences by 55.7% in the 4th quarter. Marshall Wace LLP now owns 5,813,419 shares of the medical research company's stock valued at $430,367,000 after buying an additional 2,079,642 shares during the period. Wellington Management Group LLP increased its holdings in Edwards Lifesciences by 5.3% in the 4th quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company's stock valued at $2,458,601,000 after buying an additional 1,678,154 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Edwards Lifesciences in the 4th quarter valued at $92,631,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on EW. Dbs Bank raised shares of Edwards Lifesciences to a "hold" rating in a report on Monday, June 2nd. Truist Financial lowered their price target on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Wall Street Zen lowered shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a report on Friday, May 16th. Evercore ISI boosted their price target on shares of Edwards Lifesciences from $73.00 to $77.00 and gave the company an "in-line" rating in a report on Tuesday, July 8th. Finally, Piper Sandler boosted their price target on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the company an "overweight" rating in a report on Tuesday, May 13th. One research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $80.40.

Edwards Lifesciences Price Performance

NYSE:EW traded down $0.73 during mid-day trading on Friday, reaching $78.07. 3,780,176 shares of the company were exchanged, compared to its average volume of 5,263,936. The stock has a market cap of $45.79 billion, a PE ratio of 11.15, a PEG ratio of 3.92 and a beta of 1.11. The company has a quick ratio of 3.66, a current ratio of 4.45 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12 month low of $58.93 and a 12 month high of $91.49. The company has a fifty day moving average of $76.30 and a 200 day moving average of $73.35.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.04. The company had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The company's revenue for the quarter was up 6.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.66 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling

In related news, VP Donald E. Bobo, Jr. sold 9,500 shares of the stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $69.81, for a total value of $663,195.00. Following the sale, the vice president directly owned 47,206 shares in the company, valued at $3,295,450.86. This trade represents a 16.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Bernard J. Zovighian sold 5,980 shares of the stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $74.91, for a total transaction of $447,961.80. Following the completion of the sale, the chief executive officer owned 58,284 shares in the company, valued at $4,366,054.44. This represents a 9.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 40,348 shares of company stock worth $2,977,683. 0.34% of the stock is currently owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.